Rational Combination Immunotherapy: Understand the Biology.
Identifieur interne : 000164 ( PubMed/Curation ); précédent : 000163; suivant : 000165Rational Combination Immunotherapy: Understand the Biology.
Auteurs : Howard L. Kaufman [États-Unis]Source :
- Cancer immunology research [ 2326-6074 ] ; 2017.
Descripteurs français
- KwdFr :
- MESH :
- immunologie : Carcinome pulmonaire non à petites cellules, Tumeurs du poumon.
- usage thérapeutique : Chloroquine.
- Animaux, Association de médicaments, Autophagie, Carcinome pulmonaire non à petites cellules, Humains, Immunothérapie, Tumeurs du poumon.
English descriptors
- KwdEn :
- Animals, Antineoplastic Agents, Immunological (therapeutic use), Autophagy (drug effects), CD47 Antigen (antagonists & inhibitors), CD47 Antigen (immunology), Carcinoma, Non-Small-Cell Lung (immunology), Carcinoma, Non-Small-Cell Lung (therapy), Chloroquine (therapeutic use), Drug Therapy, Combination, Humans, Immunotherapy, Lung Neoplasms (immunology), Lung Neoplasms (therapy).
- MESH :
- chemical , antagonists & inhibitors : CD47 Antigen.
- chemical , immunology : CD47 Antigen.
- chemical , therapeutic use : Antineoplastic Agents, Immunological, Chloroquine.
- drug effects : Autophagy.
- immunology : Carcinoma, Non-Small-Cell Lung, Lung Neoplasms.
- therapy : Carcinoma, Non-Small-Cell Lung, Lung Neoplasms.
- Animals, Drug Therapy, Combination, Humans, Immunotherapy.
Abstract
Selecting rational treatment combinations remains a major challenge for improving immunotherapy outcomes. In this issue of Cancer Immunology Research, Zhang and colleagues reduced tumors by inhibiting CD47 in a lung carcinoma model, a treatment that inadvertently induced autophagy through inhibition of the Akt/mTOR pathway. By also targeting autophagy, the therapeutic response improved, highlighting the importance of understanding the biology beneath antitumor immunity. Cancer Immunol Res; 5(5); 355-6. ©2017 AACRSee article by Zhang et al., p. 363.
DOI: 10.1158/2326-6066.CIR-17-0128
PubMed: 28465453
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000164
Links to Exploration step
pubmed:28465453Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rational Combination Immunotherapy: Understand the Biology.</title><author><name sortKey="Kaufman, Howard L" sort="Kaufman, Howard L" uniqKey="Kaufman H" first="Howard L" last="Kaufman">Howard L. Kaufman</name><affiliation wicri:level="2"><nlm:affiliation>Departments of Surgery and Medicine, Rutgers University, New Brunswick, New Jersey. howard.kaufman@rutgers.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Departments of Surgery and Medicine, Rutgers University, New Brunswick</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28465453</idno><idno type="pmid">28465453</idno><idno type="doi">10.1158/2326-6066.CIR-17-0128</idno><idno type="wicri:Area/PubMed/Corpus">000164</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000164</idno><idno type="wicri:Area/PubMed/Curation">000164</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000164</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Rational Combination Immunotherapy: Understand the Biology.</title><author><name sortKey="Kaufman, Howard L" sort="Kaufman, Howard L" uniqKey="Kaufman H" first="Howard L" last="Kaufman">Howard L. Kaufman</name><affiliation wicri:level="2"><nlm:affiliation>Departments of Surgery and Medicine, Rutgers University, New Brunswick, New Jersey. howard.kaufman@rutgers.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Departments of Surgery and Medicine, Rutgers University, New Brunswick</wicri:cityArea></affiliation></author></analytic><series><title level="j">Cancer immunology research</title><idno type="eISSN">2326-6074</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antineoplastic Agents, Immunological (therapeutic use)</term><term>Autophagy (drug effects)</term><term>CD47 Antigen (antagonists & inhibitors)</term><term>CD47 Antigen (immunology)</term><term>Carcinoma, Non-Small-Cell Lung (immunology)</term><term>Carcinoma, Non-Small-Cell Lung (therapy)</term><term>Chloroquine (therapeutic use)</term><term>Drug Therapy, Combination</term><term>Humans</term><term>Immunotherapy</term><term>Lung Neoplasms (immunology)</term><term>Lung Neoplasms (therapy)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Association de médicaments</term><term>Autophagie ()</term><term>Carcinome pulmonaire non à petites cellules ()</term><term>Carcinome pulmonaire non à petites cellules (immunologie)</term><term>Chloroquine (usage thérapeutique)</term><term>Humains</term><term>Immunothérapie</term><term>Tumeurs du poumon ()</term><term>Tumeurs du poumon (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>CD47 Antigen</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>CD47 Antigen</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents, Immunological</term><term>Chloroquine</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Autophagy</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Carcinome pulmonaire non à petites cellules</term><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Carcinoma, Non-Small-Cell Lung</term><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Carcinoma, Non-Small-Cell Lung</term><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Chloroquine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Drug Therapy, Combination</term><term>Humans</term><term>Immunotherapy</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Association de médicaments</term><term>Autophagie</term><term>Carcinome pulmonaire non à petites cellules</term><term>Humains</term><term>Immunothérapie</term><term>Tumeurs du poumon</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Selecting rational treatment combinations remains a major challenge for improving immunotherapy outcomes. In this issue of <i>Cancer Immunology Research</i>, Zhang and colleagues reduced tumors by inhibiting CD47 in a lung carcinoma model, a treatment that inadvertently induced autophagy through inhibition of the Akt/mTOR pathway. By also targeting autophagy, the therapeutic response improved, highlighting the importance of understanding the biology beneath antitumor immunity. <i>Cancer Immunol Res; 5(5); 355-6. ©2017 AACR</i><i>See article by Zhang et al., p. 363.</i></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28465453</PMID><DateCompleted><Year>2018</Year><Month>02</Month><Day>20</Day></DateCompleted><DateRevised><Year>2018</Year><Month>05</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2326-6074</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>5</Issue><PubDate><Year>2017</Year><Month>05</Month></PubDate></JournalIssue><Title>Cancer immunology research</Title><ISOAbbreviation>Cancer Immunol Res</ISOAbbreviation></Journal><ArticleTitle>Rational Combination Immunotherapy: Understand the Biology.</ArticleTitle><Pagination><MedlinePgn>355-356</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1158/2326-6066.CIR-17-0128</ELocationID><Abstract><AbstractText>Selecting rational treatment combinations remains a major challenge for improving immunotherapy outcomes. In this issue of <i>Cancer Immunology Research</i>, Zhang and colleagues reduced tumors by inhibiting CD47 in a lung carcinoma model, a treatment that inadvertently induced autophagy through inhibition of the Akt/mTOR pathway. By also targeting autophagy, the therapeutic response improved, highlighting the importance of understanding the biology beneath antitumor immunity. <i>Cancer Immunol Res; 5(5); 355-6. ©2017 AACR</i><i>See article by Zhang et al., p. 363.</i></AbstractText><CopyrightInformation>©2017 American Association for Cancer Research.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kaufman</LastName><ForeName>Howard L</ForeName><Initials>HL</Initials><AffiliationInfo><Affiliation>Departments of Surgery and Medicine, Rutgers University, New Brunswick, New Jersey. howard.kaufman@rutgers.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer Immunol Res</MedlineTA><NlmUniqueID>101614637</NlmUniqueID><ISSNLinking>2326-6066</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000074322">Antineoplastic Agents, Immunological</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051928">CD47 Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>886U3H6UFF</RegistryNumber><NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000074322" MajorTopicYN="N">Antineoplastic Agents, Immunological</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051928" MajorTopicYN="N">CD47 Antigen</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007167" MajorTopicYN="Y">Immunotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>5</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>5</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>2</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28465453</ArticleId><ArticleId IdType="pii">5/5/355</ArticleId><ArticleId IdType="doi">10.1158/2326-6066.CIR-17-0128</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000164 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000164 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:28465453
|texte= Rational Combination Immunotherapy: Understand the Biology.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:28465453" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |